| Immunology of COVID-19: current state of the science N Vabret, GJ Britton, C Gruber, S Hegde, J Kim, M Kuksin, R Levantovsky, ... Immunity 52 (6), 910-941, 2020 | 1683 | 2020 |
| Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction DK Wells, MM van Buuren, KK Dang, VM Hubbard-Lucey, KCF Sheehan, ... Cell 183 (3), 818-834. e13, 2020 | 335 | 2020 |
| Google correlate whitepaper M Mohebbi, D Vanderkam, J Kodysh, R Schonberger, H Choi, S Kumar See https://www. google. com/trends/correlate/whitepaper. pdf, 2011 | 100 | 2011 |
| Computational pipeline for the PGV-001 neoantigen vaccine trial A Rubinsteyn, J Kodysh, I Hodes, S Mondet, BA Aksoy, JP Finnigan, ... Frontiers in immunology 8, 1807, 2018 | 58 | 2018 |
| Landscape and selection of vaccine epitopes in SARS-CoV-2 CC Smith, KS Olsen, KM Gentry, M Sambade, W Beck, J Garness, ... Genome medicine 13 (1), 101, 2021 | 42 | 2021 |
| Bioinformatic methods for cancer neoantigen prediction S Boegel, JC Castle, J Kodysh, T O'Donnell, A Rubinsteyn Progress in molecular biology and translational science 164, 25-60, 2019 | 29 | 2019 |
| Mutations in an innate immunity pathway are associated with poor overall survival outcomes and hypoxic signaling in cancer MM Olcina, NG Balanis, RK Kim, BA Aksoy, J Kodysh, MJ Thompson, ... Cell reports 25 (13), 3721-3732. e6, 2018 | 23 | 2018 |
| Vaxrank: a computational tool for designing personalized cancer vaccines A Rubinsteyn, I Hodes, J Kodysh, J Hammerbacher Biorxiv, 142919, 2017 | 23 | 2017 |
| OpenVax: an open-source computational pipeline for cancer neoantigen prediction J Kodysh, A Rubinsteyn Bioinformatics for Cancer Immunotherapy: Methods and Protocols, 147-160, 2020 | 20 | 2020 |
| Google correlate whitepaper. 2011 M Mohebbi, D Vanderkam, J Kodysh, R Schonberger, H Choi, S Kumar | 11 | 2011 |
| Association between incidental pelvic inflammation and aggressive prostate cancer D Chakravarty, P Ratnani, L Huang, Z Dovey, S Sobotka, R Berryhill, ... Cancers 14 (11), 2734, 2022 | 5 | 2022 |
| CTIM-17. phase I study of the safety and immunogenicity of personalized neoantigen vaccines and tumor treating fields in patients with newly diagnosed glioblastoma J Kodysh, A Rubinsteyn, A Blazquez, J Mandeli, N Bhardwaj, A Hormigo Neuro-Oncology 22 (Suppl 2), ii36, 2020 | 4 | 2020 |
| A phase I study of the safety and immunogenicity of a multi-peptide personalized genomic vaccine in the adjuvant treatment of solid tumors and hematological malignancies. A Blazquez, A Rubinsteyn, J Kodysh, JP Finnigan, TU Marron, M Meseck, ... Journal of Clinical Oncology 37 (15_suppl), e14307-e14307, 2019 | 4 | 2019 |
| Immunology of COVID-19: current state of the science M Agrawal, M Aleynick, M Belabed, G Britton, M Brown, ... | 2 | 2020 |
| Abstract CT062: A Phase I study of the safety and immunogenicity of personalized mutation-derived tumor vaccine and treatment fields in patients with newly diagnosed glioblastoma A Hormigo, A Rubinsteyn, J Kodysh, A Blazquez, N Bhardwaj Cancer Research 79 (13_Supplement), CT062-CT062, 2019 | 2 | 2019 |
| 334 Phase I study of safety and activity of personalized neoantigen-based vaccines in combination with tumor treating fields for newly diagnosed glioblastoma patients J Kodysh, CC Bozkus, M Saxena, M Meseck, A Rubinsteyn, T O’Donnell, ... Journal for ImmunoTherapy of Cancer 9 (Suppl 2), 2021 | 1 | 2021 |
| Abstract LB048: An adjuvant personalized neoantigen peptide vaccine for the treatment of malignancies (PGV-001) TU Marron, M Saxena, N Bhardwaj, M Meseck, A Rubinsteyn, J Finnigan, ... Cancer Research 81 (13_Supplement), LB048-LB048, 2021 | 1 | 2021 |
| Abstract CT173: PGV-001: A phase I trial of a multipeptide personalized neoantigen vaccine in the adjuvant setting J Kodysh, T Marron, A Rubinsteyn, T O'Donnell, J Finnigan, A Blazquez, ... Cancer Research 80 (16_Supplement), CT173-CT173, 2020 | 1 | 2020 |
| Abstract LB113: Immunogenicity of Atezolizumab plus personalized neoantigen vaccination (PGV-001) in patients with urothelial cancer in adjuvant vs metastatic setting M Saxena, J Anker, J Kodysh, T O'Donnell, M Meseck, O Hapanowicz, ... Cancer Research 84 (7_Supplement), LB113-LB113, 2024 | | 2024 |
| Atezolizumab plus personalized neoantigen vaccination (PGV001) in patients with urothelial cancer. JF Anker, M Saxena, J Kodysh, T O'Donnell, M Meseck, O Hapanowicz, ... Journal of Clinical Oncology 42 (4_suppl), 597-597, 2024 | | 2024 |
